Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Operating Leases (2022 - 2025)

Historic Operating Leases for Biodesix (BDSX) over the last 4 years, with Q3 2025 value amounting to $24.4 million.

  • Biodesix's Operating Leases fell 309.24% to $24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.4 million, marking a year-over-year decrease of 309.24%. This contributed to the annual value of $24.8 million for FY2024, which is 133.13% down from last year.
  • According to the latest figures from Q3 2025, Biodesix's Operating Leases is $24.4 million, which was down 309.24% from $24.1 million recorded in Q2 2025.
  • Biodesix's Operating Leases' 5-year high stood at $25.5 million during Q2 2024, with a 5-year trough of $1.2 million in Q1 2022.
  • Moreover, its 4-year median value for Operating Leases was $24.4 million (2025), whereas its average is $17.8 million.
  • As far as peak fluctuations go, Biodesix's Operating Leases skyrocketed by 92285.47% in 2023, and later tumbled by 536.54% in 2025.
  • Over the past 4 years, Biodesix's Operating Leases (Quarter) stood at $5.3 million in 2022, then surged by 378.93% to $25.2 million in 2023, then decreased by 1.33% to $24.8 million in 2024, then dropped by 1.68% to $24.4 million in 2025.
  • Its Operating Leases was $24.4 million in Q3 2025, compared to $24.1 million in Q2 2025 and $24.5 million in Q1 2025.